Olverembatinib

奥雷巴替尼

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameOlverembatinib
Drug Alias Name耐克替尼Naiketinib奥瑞巴替尼OribatinibOrebatinib +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsStem cell growth factor receptor inhibitors
TargetsBcr-Abl tyrosine kinaseStem cell growth factor receptor
Therapy Area/IndicationsSolid tumoursHepatic InsufficiencyGastrointestinal Stromal Tumors +[8] 
Global Approved IndicationsLeukemia, Myeloid, Accelerated PhaseLeukemia, Myelogenous, Chronic
Approved Indications in ChinaLeukemia, Myeloid, Accelerated PhaseLeukemia, Myelogenous, Chronic
Original Approved Country/TerritoryMainland China
Original Approved Date2021/11/25
Country/TerritoryCzechiaCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGuangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInnovent Biologics IncAscentage Pharma Group InternationalAscentage Pharma Group Inc +[8] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursHepatic InsufficiencyGastrointestinal Stromal Tumors +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG